Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medtronic

Medtronic is going through an “aggressive transformation” to boost growth. J&J is spinning off its consumer health business to focus on its higher-growth businesses.

Better Buy: Medtronic vs. Johnson & Johnson

Colgate-Palmolive

Costco

Procter & Gamble

Lowe's

Progressive

Exxon Mobil

With the debt ceiling issue rating as perhaps the single-most critical issue for the market right now, investors should consider targeting safe-haven stocks for debt default. Naturally, the U.S. government defaulting on its obligations would probably spark a ripple effect.

7 Safe-Haven Stocks to Buy for Protection From a U.S. Debt Default Disaster

Exclusive agreement with Janssen PMP, a division of Janssen Pharmaceutica NV, to test MustGrow's mustard-based postharvest food storage preservation technologies for certain applications globally has been extended. Janssen PMP will continue to fund and drive all testing and development work.

MustGrow and Janssen PMP, a Division of Janssen Pharmaceutica NV, Extend Exclusive Global Partnership

Amgen

Johnson & Johnson's Janssen Biotech Inc has settled its lawsuit against Amgen Inc over Amgen's proposed similar version of J&J's top-selling drug Stelara, according to a filing Monday in Delaware federal court.

Amgen settles J&J patent lawsuit over drug similar to blockbuster Stelara

Apple

Advanced Micro Devices

Microsoft

NVIDIA

UnitedHealth Group

Plenty of individual stocks are notching outsized gains this year, with S&P 500 leaders Nvidia Corp. NASDAQ: NVDA and Meta Platforms Inc. NASDAQ: META more than doubling in price. Advanced Micro Devices Inc. NASDAQ: AMD leaped 63.38% higher on AI optimism, while even Royal Caribbean & plc NYSE: RCL is powering forward with a 61% year-to-date gain.

Will Dividends Take Center Stage In The Second Half Of 2023?

AbbVie

Gilead Sciences

AbbVie's current headwinds are only temporary. Gilead Sciences' business remains rock-solid.

3 Relatively Safe Stocks to Buy if a Recession Is on the Way

Applied Materials

Cabot

Discover

Evercore

National Bank Hlds

Schwab US Dividend Equity ETF

Tetra Tech

All these stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 10.8% and a median increase of 8.1%.

7 Upcoming Dividend Increases, Including 1 Dividend King

American Express

Caterpillar

Disney

JPMorgan Chase & Co

Walgreens

If you're looking to build a portfolio of high-quality blue chip stocks, Dow stocks should be at or near the top of your list. These stocks, aka the components of the Dow Jones Industrial Average (or DJIA), represent 30 of America's largest, most venerable companies, across multiple sectors.

7 High-Quality Dow Stocks to Buy on the Dip

McDonald's

Realty Income Corp

Growth investors could learn a thing or two from income-oriented investors when it comes to reliable dividend stocks. Not only do these dividend stocks pay a healthy and consistent yield, many of these names trade quite well too.

3 Reliable Dividend Stocks That Fit in Any Investor's Portfolio

There is more to the comparison, and in the sections below, we discuss why we believe BMY stock will offer higher returns than JNJ stock in the next three years.

Which Pharmaceuticals Stock Is A Better Pick: Johnson & Johnson Or Eliquis' Maker?

Coca-Cola

Investors seeking to preserve their capital are increasingly turning to defensive stocks amidst the volatility. These stocks have defensive qualities and the potential to grow dividends, supported by strong free cash flow.

Don't Panic. 3 Defensive Stocks to Diversify Into ASAP

Chevron

Horizon Pharma

Phillips 66

Paul Tudor Jones (Trades, Portfolio), founder and chief investment officer of Boston-based Tudor Investment Group, disclosed in a regulatory filing that his firm's top buys during the first quarter included new positions in Phillips 66 ( PSX , Financial) and Johnson & Johnson ( JNJ , Financial). The firm also boosted its holdings of Horizon Therapeutics ( HZNP , Financial), Chevron Corp. ( CVX , Financial) and Colgate-Palmolive Co. ( CL , Financial).

Top 5 Buys of Paul Tudor Jones' Firm in the 1st Quarter

Johnson & Johnson has set aside $400 million to resolve U.S. state consumer protection actions as part of its broader $8.9 billion effort to settle claims that its Baby Powder and other talc products cause cancer.

J&J's proposed talc settlement would pay $400 million to US state AGs

Johnson & Johnson is a Dividend King that has increased its dividend for 61 consecutive years. UnitedHealth Group should benefit from the growth of Medicare Advantage.

Which Is the Better Forever Stock: Johnson & Johnson or UnitedHealth Group?

PepsiCo

Target

Abbott Labs

American States Water

Warren Buffett is credited with saying that his preferred length of time for owning a stock is forever. To give credit where credit is due, the Oracle of Omaha does put his money where his mouth is.

Investing for the Long-Term? Here are 7 Must-Have Dividend Stocks

Altria

In good times and bad, investors want the best dividend stocks for passive income. However, it's more than just Googling the top dividend names or biggest yields.

3 Bargain Dividend Stocks to Boost Your Passive Income

AstraZeneca

Novartis

VanEck Vectors Pharmaceutical ETF

Industry-leading pharmaceutical firms are adopting artificial intelligence to drive value for the future of their enterprise. Several companies in the VanEck Pharmaceutical ETF are currently integrating AI into their operations.

How The Pharmaceutical Industry Is Using AI

Eli Lilly

Eli Lilly & Co. was on track Friday to close with a greater market capitalization than Johnson & Johnson for the first time since October 1997, according to Dow Jones Market Data.

Eli Lilly on track to close with a higher market cap than J&J for first time since 1997

News for Johnson & Johnson Stock (JNJ)